Gender dysphoria - Market Insight, Epidemiology and Market Forecast - 2030
発行: DelveInsight Business Research LLP
ページ情報: 英文 106 Pages
DelveInsight's 'Gender Dysphoria - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of gender dysphoria in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The gender dysphoria market report provides analysis regarding current treatment practices, market share of the individual therapies, and historical, current, and forecasted gender dysphoria market size from 2017 to 2030, segmented by seven major markets.
The report also covers current gender dysphoria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Gender dysphoria (GD) involves a conflict between a person's physical or assigned gender and the gender with which he/she identifies. Such people with gender dysphoria often experience significant distress and/or problems functioning associated with this conflict between the way they feel and think of themselves (referred to as experienced or expressed gender) and their physical or assigned gender. People with gender dysphoria feel victims of a biological accident and therefore live their condition as if they were cruelly imprisoned in a body incompatible with their subjective gender identity.
GD is associated with clinically significant distress and impairment in social, scholastic, and other vital functioning areas, especially when early-onset is reported.
Treatment of transgender people often includes four effective medical treatment options: counseling, cross-sex hormones, puberty suppression, and gender reassignment surgery. These treatment is optimally provided by a multidisciplinary team consisting of psychologists, endocrinologists, plastic surgeons, gynecologists, urologists, otorhinolaryngologists, and/or dermatologists. The ever-increasing social acceptance and destigmatization of children and adolescents with GD have resulted in an increased number of transgender individuals seeking endocrine care. The World Professional Association for Transgender Health (WPATH) currently publishes the standards of care (SOC) to provide clinical guidelines for the health care of transsexual, transgender, and gender non-conforming persons to maximize the health and well-being of patients with gender dysphoria.This chapter covers the details of conventional and current medical therapies available for the treatment of gender dysphoria. It also provides the country-wise gender dysphoria treatment guidelines across the United States, Europe, and Japan.
DelveInsight's gender dysphoria market report gives a thorough understanding of the disease by including details such as disease definition, etiology, development, pathophysiology, and diagnosis. It also provides gender dysphoria treatment algorithms and treatment guidelines in the US and Europe.
The Gender Dysphoria epidemiology chapters provide insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Gender dysphoria epidemiology is segmented by the total prevalent gender dysphoria cases, the gender-specific prevalence of gender dysphoria, and comorbidities associated with gender dysphoria. In addition, the report includes a thorough analysis of all segments.
Two major comorbidities associated with gender dysphoria include suicidal ideation and substance abuse. Amongst the 7MM, patients for suicidal ideation were higher than those of substance abuse.
According to DelveInsight's , the total prevalent population of Gender Dysphoria in seven major markets was 37,241 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).
Among all the seven major markets, the United States accounted for the highest number of gender dysphoria cases.
The market size of Gender Dysphoria is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest market size. Among EU5 countries, UK, in 2017, had the largest market size with USD 19.87 million, while France had the smallest market size of USD 3.74 million.
This section focuses on the rate of uptake of therapies that comprise the current treatment landscape in the gender dysphoria market during the study period, 2017-2030. Currently, the mainstay treatment option in the GD treatment landscape is hormonal therapy (HT), which includes feminizing hormone therapies and masculinizing hormone therapies. Combination of antiandrogens (spironolactone), progestins, medroxyprogesterone acetate, GnRH agonists (long-acting gonadotropin-releasing hormone-suppresses testosterone), finasteride, and estrogen (17-beta-estradiol) are the primary revenue-generating components used in the management of transgender women (male to female) and testosterone formulations are employed in case of female to male transition. The analysis covers market uptake by drugs, patient uptake by therapies, and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size. All of these will help investigate factors important in market uptake and make financial and regulatory decisions.
The dynamics of the GD market are currently a consequence of existing therapies, including high-cost surgeries. It can be summarized that basic science and human research efforts will need to be accompanied by translational approaches, where effective novel management methods and strategies are effectively translated from research settings to clinical practice.
To keep up with current market trends, we take KOLs and SME's opinion working in the gender dysphoria domain through primary research to fill the data gaps and validate our secondary research. It will help the clients assess potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.
Competitive Intelligence Analysis
We have performed the competitive and market Intelligence analysis of the gender dysphoria market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG matrix, market entry strategies etc. Also, the inclusion of the analysis entirely depends upon the data availability.
Gender Dysphoria Report Insights:
Gender Dysphoria Report Key Strengths:
Gender Dysphoria Report Assessment:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
Reasons to buy:
Which geography accounted for the largest Gender Dysphoria market size?
The United States accounted for the largest gender dysphoria market size.
What is forecasted Gender Dysphoria size in 2030?
DelveInsight estimates an increase in gender dysphoria market size during the study period, 2017-2030.
What are the present Gender Dysphoria drivers?
Absence of therapies in the market, increase in the affected population, improvement in diagnostic criteria etc.
What are the Gender Dysphoria market barriers?
Variations in epidemiological data, barriers associated with treatment, shortcomings associated with trials.
How many companies are developing drugs for Gender Dysphoria?
Currently, pharma companies are not working towards developing a therapy for gender dysphoria.
How is epidemiology segmented for soft tissue sarcoma?
It is segmented as total prevalent gender dysphoria cases, the gender-specific prevalence of gender dysphoria, and comorbidities associated with gender dysphoria
World Professional Association for Transgender Health (WPATH) Guidelines
Endocrine Society Guidelines